```html

Obstructive Coronary Artery Disease (CAD)

Overview

Obstructive coronary artery disease (CAD) is a condition in which atherosclerotic plaques narrow (≥50 % luminal narrowing) or completely block one or more of the coronary arteries that supply oxygen‑rich blood to the heart muscle. The reduced blood flow can lead to angina, myocardial infarction (heart attack), heart failure, or sudden cardiac death.

CAD is the most common type of heart disease worldwide. According to the World Health Organization (WHO), ≈ 126 million adults worldwide have diagnosed CAD, and it accounts for ~ 9 million deaths each year, making it the leading cause of death globally.<sup>[1] WHO, 2023</sup> In the United States, the Centers for Disease Control and Prevention (CDC) estimates that about 18.2 million adults have coronary artery disease, with prevalence increasing sharply after age 45 in men and age 55 in women.<sup>[2] CDC, 2022</sup>

Although CAD can affect anyone, certain groups are disproportionately impacted:

• Age: Risk rises with each decade after 40.
• Sex: Men develop obstructive CAD about 10 years earlier than women; after menopause, women’s risk catches up.
• Ethnicity: African‑American, Hispanic, and South Asian populations have higher rates of early‑onset CAD.

Symptoms

Symptoms depend on the extent of arterial blockage, the size of the affected vessel, and the heart’s oxygen demand. Many people with early CAD are asymptomatic (“silent” disease), but classic and atypical presentations include:

Typical (Anginal) Chest Pain

• Stable angina: Pressure, squeezing, or heaviness in the chest, often triggered by exertion or emotional stress and relieved by rest or nitroglycerin.
• Unstable angina: New or worsening chest discomfort that occurs at rest, lasts longer, or is less responsive to nitroglycerin—signals an imminent heart attack.

Radiating Pain

• Discomfort may radiate to the left arm, shoulder, neck, jaw, or back.
• Women, diabetics, and older adults often experience atypical radiation (e.g., to the epigastrium or lower back).

Shortness of Breath (Dyspnea)

• Occurs when the heart cannot meet the body’s oxygen demand.
• May be the dominant symptom in people with heart failure secondary to CAD.

Other Symptoms

• Fatigue or weakness: Especially with exertion.
• Palpitations: Irregular heartbeats that can accompany ischemia.
• Nausea, indigestion, or a “full” feeling: Frequently misinterpreted as gastrointestinal upset.
• Cold sweats (diaphoresis): Common during acute coronary syndromes.

Causes and Risk Factors

Obstructive CAD is caused by the progressive buildup of atherosclerotic plaque within the coronary arteries. Plaque consists of cholesterol, inflammatory cells, calcium, and fibrous tissue. Over time, the plaque can:

• Grow in size, narrowing the arterial lumen.
• Rupture, triggering a blood clot (thrombus) that acutely blocks flow.

Major Modifiable Risk Factors

• High low‑density lipoprotein (LDL) cholesterol: > 130 mg/dL is associated with faster plaque progression.<sup>[3] NIH, 2022</sup>
• Hypertension: Systolic ≥ 130 mm Hg or diastolic ≥ 80 mm Hg.
• Smoking: Current cigarettes or long‑term exposure to tobacco smoke.
• Diabetes mellitus: Increases risk 2‑4‑fold; tight glycemic control reduces progression.
• Obesity (BMI ≥ 30 kg/m²) and sedentary lifestyle: Promote dyslipidemia, hypertension, and insulin resistance.
• Unhealthy diet: High saturated fat, trans‑fat, and refined carbohydrate intake.

Non‑modifiable Risk Factors

• Age, male sex, family history of premature CAD (first‑degree relative < 55 y men, < 65 y women).
• Genetic conditions (e.g., familial hypercholesterolemia).
• Chronic inflammatory diseases (e.g., rheumatoid arthritis, lupus).
• History of pre‑eclampsia or gestational diabetes (women).

Diagnosis

Diagnosing obstructive CAD involves confirming the presence of ≥ 50 % luminal narrowing that correlates with symptoms or risk. The work‑up usually follows a stepwise approach:

Initial Evaluation

• Medical history and physical exam: Focus on chest pain characteristics, risk‑factor profile, and signs of heart failure.
• Resting electrocardiogram (ECG): May show prior infarction, left ventricular hypertrophy, or ischemic changes.
• Blood tests: Cardiac troponin (rules out acute MI), lipid panel, fasting glucose/HbA1c, kidney function.

Non‑invasive Imaging

• Stress testing (exercise or pharmacologic): Detects inducible ischemia via ECG, nuclear perfusion imaging, or stress echocardiography.
• Coronary computed tomographic angiography (CCTA): Provides high‑resolution images of the coronary lumen and plaque composition; useful for intermediate‑risk patients.
• Cardiac magnetic resonance (CMR) stress perfusion: Offers radiation‑free assessment of myocardial blood flow.

Invasive Testing

• Coronary angiography (cardiac catheterization): Gold standard; visualizes the exact degree of obstruction and allows immediate intervention (angioplasty, stent placement).
• Intravascular ultrasound (IVUS) or optical coherence tomography (OCT): Provide detailed plaque morphology during angiography.

Functional Assessment

• Fractional flow reserve (FFR): Measures pressure differences across a lesion; an FFR ≤ 0.80 generally indicates hemodynamically significant obstruction.

Treatment Options

Therapy is tailored to disease severity, symptom burden, and individual risk profile. The overarching goals are to relieve symptoms, prevent myocardial injury, and reduce mortality.

1. Lifestyle Modification (First‑line)

• Quit smoking (behavioral counseling, nicotine replacement, prescription meds).
• Adopt a Mediterranean‑style diet—high in fruits, vegetables, whole grains, nuts, olive oil; limited red meat and processed foods.
• Aim for at least **150 min/week** moderate‑intensity aerobic exercise (or 75 min vigorous) as tolerated.
• Weight loss goal: 5‑10 % of body weight if BMI ≥ 30 kg/m².
• Limit alcohol to ≤ 1 drink/day (women) or ≤ 2 drinks/day (men).

2. Pharmacologic Therapy

Medication Class	Key Drugs	Purpose
Antiplatelet agents	Aspirin 81 mg daily; Clopidogrel, Ticagrelor	Prevent clot formation on atherosclerotic plaque.
Statins (LDL‑lowering)	Atorvastatin, Rosuvastatin	Reduce plaque progression & lower CV mortality.
Beta‑blockers	Metoprolol, Carvedilol	Decrease myocardial oxygen demand; improve angina.
ACE inhibitors/ARBs	Lisinopril, Losartan	Control blood pressure, improve endothelial function.
Nitrates	Isosorbide dinitrate, Sublingual nitroglycerin	Acute relief of chest pain.
Calcium‑channel blockers	Amlodipine, Diltiazem	Neutral or reduce coronary vasospasm; aid angina control.
PCSK9 inhibitors	Alirocumab, Evolocumab	For patients with familial hypercholesterolemia or statin intolerance.

3. Revascularization Procedures

• Percutaneous coronary intervention (PCI): Balloon angioplasty with stent placement. Preferred for single‑vessel disease, acute coronary syndromes, or when anatomy is suitable.
• Coronary artery bypass grafting (CABG): Surgical bypass using saphenous vein or internal mammary artery grafts. Indicated for left main disease, three‑vessel disease, or diabetics with multi‑vessel disease.
• Decision between PCI and CABG is guided by SYNTAX score, disease complexity, comorbidities, and patient preference.<sup>[4] ACC/AHA Guidelines, 2021</sup>

4. Emerging/Adjunctive Therapies

• Anti‑inflammatory agents: Low‑dose colchicine (0.5 mg daily) showed reduced CV events in the COLCOT trial.
• RNA‑based therapies (e.g., inclisiran): Offer sustained LDL‑lowering with twice‑yearly dosing.
• Cardiac rehabilitation programs improve functional capacity and adherence to medical therapy.

Living with Obstructive Coronary Artery Disease

Managing CAD is a lifelong partnership between you, your cardiologist, and your primary‑care team.

Daily Management Checklist

• Medication adherence: Use a pillbox or phone reminders; never stop a drug without consulting your doctor.
• Blood pressure & cholesterol monitoring: Aim for < 130/80 mm Hg and LDL < 70 mg/dL (or < 55 mg/dL for very high risk).
• Weight & waist circumference: Track weekly; a modest 5‑% loss improves outcomes.
• Physical activity: Start with short walks, gradually increase intensity. Consider a cardiac rehab program.
• Stress management: Mindfulness, yoga, or counseling can lower blood pressure and improve quality of life.
• Vaccinations: Flu and COVID‑19 vaccines reduce the risk of infection‑related cardiac events.

Psychosocial Support

Depression and anxiety are common after a CAD diagnosis and can worsen prognosis. Speak to a mental‑health professional, join a support group, or use reputable online communities.

When to Call Your Doctor

• New or worsening chest pain or shortness of breath.
• Palpitations, fainting, or dramatic weight gain/edema.
• Side effects from medications (e.g., muscle pain with statins, severe cough with ACE inhibitors).

Prevention

Because atherosclerosis begins early, primary prevention focuses on risk‑factor control long before symptoms appear.

Key Preventive Strategies

1. Control blood pressure: < 130/80 mm Hg target; lifestyle changes + medications.
2. Lower LDL cholesterol: Statin therapy for anyone with ≥ 7.5 % 10‑year ASCVD risk; consider PCSK9 inhibitors if goals not met.
3. Maintain a healthy weight: BMI 18.5‑24.9 kg/m²; waist < 40 in (men) or < 35 in (women).
4. Quit tobacco: Seek counseling, nicotine replacement, or prescription aids (varenicline, bupropion).
5. Exercise regularly: At least 150 min moderate aerobic activity weekly; incorporate resistance training twice weekly.
6. Adopt a heart‑healthy diet: Emphasize fiber, omega‑3 fatty acids, plant sterols; limit sodium to < 2 g/day.
7. Screen for diabetes: Fasting glucose ≥ 126 mg/dL or HbA1c ≥ 6.5 % warrants intervention.

Complications

If obstructive CAD is left untreated or inadequately managed, several serious complications can arise:

• Myocardial infarction (heart attack): Complete occlusion leads to irreversible heart‑muscle damage.
• Heart failure: Chronic ischemia weakens the left ventricle, causing reduced ejection fraction.
• Life‑threatening arrhythmias: Ventricular tachycardia/fibrillation may result in sudden cardiac death.
• Stroke: Atherosclerotic plaque can embolize or coexist with cerebrovascular disease.
• Peripheral artery disease & renal artery stenosis: Systemic atherosclerosis affecting other vessels.
• Procedural complications: Bleeding, contrast‑induced nephropathy, or stent thrombosis after PCI.

When to Seek Emergency Care

---

Sources: [1] World Health Organization. Cardiovascular diseases (CVD) fact sheet, 2023. [2] CDC. Heart Disease and Stroke Statistics—2022 Update. [3] National Institutes of Health. Lipid Management Guidelines, 2022. [4] 2021 ACC/AHA Guideline for the Management of Patients With Stable Ischemic Heart Disease.

```